Skip to main content

Taysha Gene Therapies, Inc. (TSHA)

Sector
Biotechnology
Last price
$4.00
As of

Kresmion compiles this page from TSHA's SEC filings, its 13F institutional holders and the market events Kresmion detects, each linked to its source.

Taysha Gene Therapies, Inc. (TSHA): no institutional manager tracked by Kresmion reported a non-option position in the latest Form 13F reporting quarter, and the most recent SEC filing on record for the company is a Form 10-Q filed 2026-11-12.

As of . Source: SEC EDGAR filings for TSHA. Method and limitations.

COMPANY DOSSIER

See the full TSHA dossier

Price with insider and filing markers, who is positioning, fundamentals and peers for TSHA on one page. Preview it with sample data, then open it live with a free account.

Preview the TSHA dossier

Active events for TSHA

FREE, NO ACCOUNT

Every event on TSHA, as it fires

New filings, 13F moves and cross asset events on TSHA land in the record first.

Get it by email

No fixed schedule: it goes out when the data has something in it. Unsubscribe anytime. We never sell your data.

Join on Telegram
Join on Telegram

One tap. Live alerts, no email needed.

No non-option holdings from tracked managers in this reporting quarter. Other reporting quarters are linked above.

Recent SEC filings, TSHA

More data on TSHA

TSHA against its peers

TSHA's operating margin of -1130.6% ranks in the 38th percentile of 11 Biotechnology sub-industry peers, fiscal period ending 2025-12-31.

MetricTSHAPeer medianPercentilen
Revenue FY9.8M USD67.7M USD3811
Gross marginn/a90.9%n/a6
Operating margin-1130.6%-239.8%3811
Net margin-1115.3%-170.1%3811
Return on equity-44.1%-38.8%4715
1 year1.2%19.7%3819

Peers (20): URGN, GHRS, INBX, ABSI, DMRA, LBRX, MLYS, NTLA, MNKD, KRSA, ANAB, NVAX, SLN, VOR, IMCR, TYRA, CMPS, RAPP, SLS, QURE. Left out: AVLN (no annual filing), AAPG (period gap), KALV.D (no annual filing), KARD (no annual filing), ADRX (no annual filing). Fiscal period ending 2025-12-31. Every figure is one full fiscal year read from one annual filing (TSHA: 10-K), reported in USD. Nothing is trailing twelve months and nothing is converted between currencies. Source: SEC EDGAR XBRL company facts (public domain); prices from Kresmion's daily equity market-data snapshot. Open the full comparison.

Cite this data

Kresmion counts the managers it follows that reported a non-option position in TSHA on Form 13F-HR for the latest reporting quarter, orders those positions by the value each filing reports, and lists the company's latest SEC filings and the events Kresmion recorded on TSHA in the last 180 days.

Upstream: SEC EDGAR filings for TSHA

Kresmion, "Taysha Gene Therapies, Inc. (TSHA) institutional holdings and SEC filings", data as of 2026-11-14, https://kresmion.com/research/TSHA. Upstream data: SEC EDGAR filings for TSHA.

Link to this data (HTML):

<a href="https://kresmion.com/research/TSHA">Taysha Gene Therapies, Inc. (TSHA) institutional holdings and SEC filings (Kresmion)</a>

Writing about this? Press contact and ready-to-quote figures

Follow TSHA on a live board

Kresmion is a source-first market terminal for cross-asset market intelligence. Open a board scoped to TSHA for its filings, 13F changes, insider trades, options positioning, and confluence read in one view, each with its source.

Preview the TSHA dossier
Share

The TSHA intelligence card: the smart money composite, cross family confluence and the top current signal, with a link back to this page.